NRX Pharmaceuticals Inc
NRXP
查看详细走势图
2.370USD
+0.190+8.72%
收盘 12/19, 16:00（美东）报价延迟15分钟
65.61M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+8.72%
5天
+14.49%
1月
+11.27%
6月
-27.30%
今年开始到现在
+7.73%
1年
+58.00%
查看详细走势图
TradingKey NRX Pharmaceuticals Inc股票评分
单位: USD 更新时间: 2025-10-27操作建议
当前估值合理，机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价max_target_price。目前股价在压力位和支撑位之间，可以做区间波段操作。
NRX Pharmaceuticals Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
4
位分析师
买入
评级
36.500
目标均价
+1515.04%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
NRX Pharmaceuticals Inc亮点
亮点风险
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing therapeutics based on its N-methyl-D-aspartate (NMDA) platform for the treatment of central nervous system disorders, specifically suicidal depression, chronic pain, and PTSD. It is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101, (oral D-cycloserine/lurasidone). NRX-100 has been awarded Fast Track Designation for the treatment of Suicidal Ideation in Depression, including Bipolar Depression. NRX-101 has been awarded Breakthrough Therapy Designation for the treatment of suicidal bipolar depression. NRx has filed an Abbreviated New Drug Application (ANDA) and initiated a New Drug Application filing for NRX-100 (IV ketamine) with an application for the Commissioner’s National Priority Voucher Program for the treatment of suicidal depression. Its subsidiary, HOPE Therapeutics, Inc., is a healthcare delivery company that is building a network of interventional psychiatry clinics.
NRX Pharmaceuticals Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
NRX Pharmaceuticals Inc简介
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing therapeutics based on its N-methyl-D-aspartate (NMDA) platform for the treatment of central nervous system disorders, specifically suicidal depression, chronic pain, and PTSD. It is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101, (oral D-cycloserine/lurasidone). NRX-100 has been awarded Fast Track Designation for the treatment of Suicidal Ideation in Depression, including Bipolar Depression. NRX-101 has been awarded Breakthrough Therapy Designation for the treatment of suicidal bipolar depression. NRx has filed an Abbreviated New Drug Application (ANDA) and initiated a New Drug Application filing for NRX-100 (IV ketamine) with an application for the Commissioner’s National Priority Voucher Program for the treatment of suicidal depression. Its subsidiary, HOPE Therapeutics, Inc., is a healthcare delivery company that is building a network of interventional psychiatry clinics.
公司代码NRXP
公司NRX Pharmaceuticals Inc
CEOJavitt (Jonathan C)
网址https://www.nrxpharma.com/
常见问题
NRX Pharmaceuticals Inc(NRXP)的当前股价是多少？
NRX Pharmaceuticals Inc(NRXP)的当前股价是 2.370。
NRX Pharmaceuticals Inc的股票代码是什么？
NRX Pharmaceuticals Inc的股票代码是NRXP。
NRX Pharmaceuticals Inc股票的52周最高点是多少？
NRX Pharmaceuticals Inc股票的52周最高点是6.010。
NRX Pharmaceuticals Inc股票的52周最低点是多少？
NRX Pharmaceuticals Inc股票的52周最低点是1.400。
NRX Pharmaceuticals Inc的市值是多少？
NRX Pharmaceuticals Inc的市值是65.61M。
NRX Pharmaceuticals Inc的净利润是多少？
NRX Pharmaceuticals Inc的净利润为-25.13M。
现在NRX Pharmaceuticals Inc(NRXP)的股票是买入、持有还是卖出？
根据分析师评级，NRX Pharmaceuticals Inc(NRXP)的总体评级为买入，目标价格为36.500。
NRX Pharmaceuticals Inc(NRXP)股票的每股收益（EPS TTM）是多少
NRX Pharmaceuticals Inc(NRXP)股票的每股收益（EPS TTM）是-2.308。
相关品种
